000 | 01168 a2200349 4500 | ||
---|---|---|---|
005 | 20250517221943.0 | ||
264 | 0 | _c20190124 | |
008 | 201901s 0 0 hun d | ||
022 | _a0019-1442 | ||
024 | 7 |
_a10.18071/isz.70.0185 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aGombos, Barbara | |
245 | 0 | 0 |
_a[Experience with natalizumab-treatment at Semmelweis University]. _h[electronic resource] |
260 |
_bIdeggyogyaszati szemle _cMay 2017 |
||
300 |
_a185-191 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 | _aAcademic Medical Centers |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aImmunologic Factors _xtherapeutic use |
650 | 0 | 4 | _aImmunomodulation |
650 | 0 | 4 |
_aMultiple Sclerosis _xdiagnostic imaging |
650 | 0 | 4 |
_aNatalizumab _xtherapeutic use |
650 | 0 | 4 | _aQuality of Life |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 | _aUniversities |
700 | 1 | _aIljicsov, Anna | |
700 | 1 | _aBarsi, Péter | |
700 | 1 | _aHegedüs, Katalin | |
700 | 1 | _aSimó, Magdolna | |
773 | 0 |
_tIdeggyogyaszati szemle _gvol. 70 _gno. 5-6 _gp. 185-191 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.18071/isz.70.0185 _zAvailable from publisher's website |
999 |
_c28499022 _d28499022 |